Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05778864 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05778864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05778864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
March 17, 2023
Completion date
September 6, 2024
Enrollment
47 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

renal insufficiency